Skip to content

Routine obstetric medications and maternal heart rate variability

Routine obstetric medications and maternal heart rate variability

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON23599
Enrollment
61
Registered
2019-12-06
Start date
2020-04-06
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypertensive disorders of pregnancy (HDP), threatened preterm birth (TPB), preterm premature rupture of membranes (PPROM), vaginal blood loss

Interventions

None listed

Sponsors

Philips Electronics Nederland B.V.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - Aged 18 years and above - Gestational age 23 5/7 to 33 6/7 weeks upon admission - Yet to receive second dose of antenatal corticosteroids - Proficient in Dutch or English

Exclusion criteria

Exclusion criteria: - History of cardiovascular disease, specifically severe arrhythmia and congenital heart disease - Cushing’s disease - Known allergies for hard plastic (like in sport watches) or elastic band material. - Presence of wounds, injuries or infectious diseases on the skin where the wrist-wearable device will be placed. - Tattoo on top of wrist (where sensor should be placed) - No space to place the device (as judged by the health care practitioner placing the device) - Dexamethasone is given as antenatal corticosteroid instead of Betamethasone

Design outcomes

Primary

MeasureTime frame
Investigate the effect of routine obstetric medications on maternal PPG features in complicated pregnancies, with specific focus on heart rate variability.

Secondary

MeasureTime frame
Investigate PPG features of women who deliver preterm. Investigate the PPG features throughout different stages of delivery (compared to CTG data) Investigate differences in PPG features between normotensive and hypertensive subjects. Investigate PPG features at 6 weeks postpartum.

Contacts

Public ContactMaretha Bester

Philips Research

maretha.bester@philips.com+31 40 279 1111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)